Early Detection of Inflammation Biomarkers to Identify Risk in Sepsis and Infection

What this Trial Is About

Researchers are evaluating early biomarkers of infection and inflammation to identify patients at risk for poor outcomes in sepsis and septic shock. The study focuses on measuring immune response markers like cytokines, clotting factors, and endothelial markers to better understand sepsis severity and patient risk. It is a multicenter observational pilot study comparing patients with suspected infection to a non-infected control group. Participants include patients suspected of infection and a control group without infection. Blood samples and chart reviews are collected at enrollment, 24, 48, and 72 hours for the infected group, while controls have a single blood draw at enrollment. Additional assessments include non-invasive imaging techniques like orthogonal polarization spectroscopy, echocardiography, diffuse correlation spectroscopy, and measurements of microvascular flow and endothelial glycocalyx degradation. Throughout the study, participants undergo physiological assessments such as echocardiography and microcirculation imaging. Researchers track outcomes including 28-day in-hospital mortality and organ dysfunction by SOFA score within 24 hours. The study involves urine sample collection for some patients and uses various non-invasive monitors to gather detailed information on the bodys response to infection and inflammation over several days.

Biomarkers in Infection